OC.53 Use of the CD19/CD3 T cell engager blinatumomab in refractory systemic sclerosis: a case series
Jerome Avouac(Université Paris Cité), Yannick Allanore, Emmanuel Chatelus(Laboratoire National de Référence), Justine Decroocq(Centre National de la Recherche Scientifique), A. El Aatmani(Hôpitaux Universitaires de Strasbourg), T. Martin(Hôpital Civil, Strasbourg), Marie Laure Brandely-Piat(Hôpital Cochin), Jean Sibilia, Stephane Hilliquin(Université Paris Cité), Roberto d’Alessandro(Université Paris Cité), Yannick Dieudonné(Inserm), Marc Scherlinger, Didier Bouscary(Université Paris Cité)
Cited by 0
Related Papers
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
|Blood|2015|383
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
|Haematologica|2009|316